Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Leukemia, Myeloid, Chronic-Phase 4Leukemia 3Bronchiolitis Obliterans Syndrome 3Philadelphia Chromosome 2Myeloproliferative Disorders 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1P1b: Advanced Solid Tumors 1Leukemia, Myeloid 1Hematologic Diseases 1Blast Crisis 1Advanced Solid Tumors 1

Interventions

Imatinib Mesylate 8venetoclax 6Cytarabine 5ponatinib 4nilotinib 4Azacitidine 4zosuquidar trihydrochloride 2fludarabine 2bosutinib 2RO6839921 2Decitabine 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1pulrodemstat besilate 1posaconazole 1pegfilgrastim 1lestaurtinib 1gilteritinib 1flumatinib 1enasidenib 1emvododstat 1blinatumomab 1asciminib 1Whole-Body Irradiation 1N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide 1Lenalidomide 1Immunotherapy, Adoptive 1Idarubicin 1IMC-EB10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid × asciminib × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡